首页 > 最新文献

World Journal of Gastrointestinal Oncology最新文献

英文 中文
Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis. 肝动脉灌注化疗及其联合策略治疗晚期肝细胞癌的疗效:一项网络荟萃分析。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3672
Shun-An Zhou, Qing-Mei Zhou, Lei Wu, Zhi-Hong Chen, Fan Wu, Zhen-Rong Chen, Lian-Qun Xu, Bi-Ling Gan, Hao-Sheng Jin, Ning Shi

Background: With the rapid progress of systematic therapy for hepatocellular carcinoma (HCC), therapeutic strategies combining hepatic arterial infusion chemotherapy (HAIC) with systematic therapy arised increasing concentrations. However, there have been no systematic review comparing HAIC and its combination strategies in the first-line treatment for advanced HCC.

Aim: To investigate the efficacy and safety of HAIC and its combination therapies for advanced HCC.

Methods: A network meta-analysis was performed by including 9 randomized controlled trails and 35 cohort studies to carry out our study. The outcomes of interest comprised overall survival (OS), progression-free survival (PFS), tumor response and adverse events. Hazard ratios (HR) and odds ratios (OR) with a 95% confidence interval (CI) were calculated and agents were ranked based on their ranking probability.

Results: HAIC outperformed Sorafenib (HR = 0.55, 95%CI: 0.42-0.72; HR = 0.51, 95%CI: 0.33-0.78; OR = 2.86, 95%CI: 1.37-5.98; OR = 5.45, 95%CI: 3.57-8.30; OR = 7.15, 95%CI: 4.06-12.58; OR = 2.89, 95%CI: 1.99-4.19; OR = 0.48, 95%CI: 0.25-0.92, respectively) and transarterial chemoembolization (TACE) (HR = 0.50, 95%CI: 0.33-0.75; HR = 0.62, 95%CI: 0.39-0.98; OR = 3.08, 95%CI: 1.36-6.98; OR = 2.07, 95%CI: 1.54-2.80; OR = 3.16, 95%CI: 1.71-5.85; OR = 2.67, 95%CI: 1.59-4.50; OR = 0.16, 95%CI: 0.05-0.54, respectively) in terms of efficacy and safety. HAIC + lenvatinib + ablation, HAIC + ablation, HAIC + anti- programmed cell death 1 (PD-1), and HAIC + radiotherapy had the higher likelihood of providing better OS and PFS outcomes compared to HAIC alone. HAIC + TACE + S-1, HAIC + lenvatinib, HAIC + PD-1, HAIC + TACE, and HAIC + sorafenib had the higher likelihood of providing better partial response and objective response rate outcomes compared to HAIC. HAIC + PD-1, HAIC + TACE + S-1 and HAIC + TACE had the higher likelihood of providing better complete response and disease control rate outcomes compared to HAIC alone.

Conclusion: HAIC proved more effective and safer than sorafenib and TACE. Furthermore, combined with other interventions, HAIC showed improved efficacy over HAIC monotherapy according to the treatment ranking analysis.

背景:随着肝细胞癌(HCC)系统治疗的快速发展,肝动脉灌注化疗(HAIC)与系统治疗相结合的治疗策略越来越受到重视。目的:探讨肝动脉灌注化疗及其联合疗法治疗晚期肝癌的有效性和安全性:我们进行了一项网络荟萃分析,包括 9 项随机对照试验和 35 项队列研究。研究结果包括总生存期(OS)、无进展生存期(PFS)、肿瘤反应和不良事件。研究计算了危险比(HR)和几率比(OR)及95%置信区间(CI),并根据排序概率对药物进行了排序:HAIC的疗效优于索拉非尼(HR = 0.55,95%CI:0.42-0.72;HR = 0.51,95%CI:0.33-0.78;OR = 2.86,95%CI:1.37-5.98;OR = 5.45,95%CI:3.57-8.30;OR = 7.15,95%CI:4.06-12.58;OR = 2.89,95%CI:1.99-4.19;OR = 0.48,95%CI:0.25-0.92)和经动脉化疗栓塞(TACE)(HR = 0.50,95%CI:0.33-0.75;HR = 0.62,95%CI:0.39-0.98;OR = 3.08,95%CI:1.36-6.98;OR = 2.07,95%CI:1.54-2.80;OR = 3.16,95%CI:1.71-5.85;OR = 2.67,95%CI:1.59-4.50;OR = 0.16,95%CI:0.05-0.54)的疗效和安全性。与单用HAIC相比,HAIC+来伐替尼+消融、HAIC+消融、HAIC+抗程序性细胞死亡1(PD-1)和HAIC+放疗更有可能提供更好的OS和PFS结果。与HAIC相比,HAIC + TACE + S-1、HAIC +来伐替尼、HAIC + PD-1、HAIC + TACE和HAIC +索拉非尼更有可能提供更好的部分应答和客观应答率结果。与单用HAIC相比,HAIC + PD-1、HAIC + TACE + S-1和HAIC + TACE更有可能提供更好的完全应答和疾病控制率结果:结论:事实证明,HAIC比索拉非尼和TACE更有效、更安全。结论:事实证明,HAIC比索拉非尼和TACE更有效、更安全。此外,根据疗效排序分析,HAIC联合其他干预措施的疗效优于HAIC单药治疗。
{"title":"Efficacy of hepatic arterial infusion chemotherapy and its combination strategies for advanced hepatocellular carcinoma: A network meta-analysis.","authors":"Shun-An Zhou, Qing-Mei Zhou, Lei Wu, Zhi-Hong Chen, Fan Wu, Zhen-Rong Chen, Lian-Qun Xu, Bi-Ling Gan, Hao-Sheng Jin, Ning Shi","doi":"10.4251/wjgo.v16.i8.3672","DOIUrl":"10.4251/wjgo.v16.i8.3672","url":null,"abstract":"<p><strong>Background: </strong>With the rapid progress of systematic therapy for hepatocellular carcinoma (HCC), therapeutic strategies combining hepatic arterial infusion chemotherapy (HAIC) with systematic therapy arised increasing concentrations. However, there have been no systematic review comparing HAIC and its combination strategies in the first-line treatment for advanced HCC.</p><p><strong>Aim: </strong>To investigate the efficacy and safety of HAIC and its combination therapies for advanced HCC.</p><p><strong>Methods: </strong>A network meta-analysis was performed by including 9 randomized controlled trails and 35 cohort studies to carry out our study. The outcomes of interest comprised overall survival (OS), progression-free survival (PFS), tumor response and adverse events. Hazard ratios (HR) and odds ratios (OR) with a 95% confidence interval (CI) were calculated and agents were ranked based on their ranking probability.</p><p><strong>Results: </strong>HAIC outperformed Sorafenib (HR = 0.55, 95%CI: 0.42-0.72; HR = 0.51, 95%CI: 0.33-0.78; OR = 2.86, 95%CI: 1.37-5.98; OR = 5.45, 95%CI: 3.57-8.30; OR = 7.15, 95%CI: 4.06-12.58; OR = 2.89, 95%CI: 1.99-4.19; OR = 0.48, 95%CI: 0.25-0.92, respectively) and transarterial chemoembolization (TACE) (HR = 0.50, 95%CI: 0.33-0.75; HR = 0.62, 95%CI: 0.39-0.98; OR = 3.08, 95%CI: 1.36-6.98; OR = 2.07, 95%CI: 1.54-2.80; OR = 3.16, 95%CI: 1.71-5.85; OR = 2.67, 95%CI: 1.59-4.50; OR = 0.16, 95%CI: 0.05-0.54, respectively) in terms of efficacy and safety. HAIC + lenvatinib + ablation, HAIC + ablation, HAIC + anti- programmed cell death 1 (PD-1), and HAIC + radiotherapy had the higher likelihood of providing better OS and PFS outcomes compared to HAIC alone. HAIC + TACE + S-1, HAIC + lenvatinib, HAIC + PD-1, HAIC + TACE, and HAIC + sorafenib had the higher likelihood of providing better partial response and objective response rate outcomes compared to HAIC. HAIC + PD-1, HAIC + TACE + S-1 and HAIC + TACE had the higher likelihood of providing better complete response and disease control rate outcomes compared to HAIC alone.</p><p><strong>Conclusion: </strong>HAIC proved more effective and safer than sorafenib and TACE. Furthermore, combined with other interventions, HAIC showed improved efficacy over HAIC monotherapy according to the treatment ranking analysis.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Application of fecal immunochemical test in colorectal cancer screening: A community-based, cross-sectional study in average-risk individuals in Hainan. 粪便免疫化学检验在大肠癌筛查中的应用:一项基于社区的横断面研究,针对海南的平均风险人群。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3445
Fan Zeng, Da-Ya Zhang, Shi-Ju Chen, Run-Xiang Chen, Chen Chen, Shi-Mei Huang, Da Li, Xiao-Dong Zhang, Jia-Jia Chen, Cui-Yi Mo, Lei Gao, Jun-Tao Zeng, Jian-Xin Xiong, Zhai Chen, Fei-Hu Bai

Background: The incidence of colorectal cancer (CRC) in China is steadily rising, with a high proportion of advanced-stage diagnoses. This highlights the significance of early detection and prevention measures to enhance survival rates. Fecal immunochemical testing (FIT) is a globally recommended CRC screening method; however, limited research has been conducted on its application in Hainan.

Aim: To assess the efficacy and adherence of FIT screening among average-risk individuals in Hainan, while also examining the risk factors associated with positive FIT results.

Methods: This population-based cross-sectional study implemented FIT screening for CRC in 2000 asymptomatic participants aged 40-75 years from five cities and 21 community health centers in Hainan Province. The study was conducted from August 2022 to April 2023, employing a stratified sampling method to select participants. Individuals with positive FIT results subsequently underwent colonoscopy. Positive predictive values for confirmed CRC and advanced adenoma were calculated, and the relationship between relevant variables and positive FIT results was analyzed using χ 2 tests and multivariate logistic regression.

Results: A total of 1788 participants completed the FIT screening, with a median age of 57 years (interquartile range: 40-75). Among them, 503 (28.1%) were males, and 1285 (71.9%) were females, resulting in an 89.4% compliance rate for FIT screening. The overall positivity rate of FIT was 4.4% [79 out of 1788; 95% confidence interval (CI): 3%-5%]. The specific positivity rates for Haikou, Sanya, Orient City, Qionghai City, and Wuzhishan City were 9.6% (45 of 468; 95%CI: 8%-11%), 1.3% (6 of 445; 95%CI: 0.1%-3.1%), 2.7% (8 of 293; 95%CI: 1.2%-4.3%), 3.3% (9 of 276; 95%CI: 1.0%-6.3%), and 4.2% (11 of 406; 95%CI: 1.2%-7.3%), respectively. Significant associations were found between age, dietary habits, and positive FIT results. Out of the 79 participants with positive FIT results, 55 underwent colonoscopy, demonstrating an 82.2% compliance rate. Among them, 10 had a clean gastrointestinal tract, 43 had polyps or adenomas, and 2 were confirmed to have CRC, yielding a positive predictive value of 3.6% (95%CI: 0.9%-4.2%). Among the 43 participants with polyps or adenomas, 8 were diagnosed with advanced adenomas, resulting in an advanced adenoma rate of 14.5% (95%CI: 10.1%-17.7%).

Conclusion: In the Hainan region, FIT screening for CRC among asymptomatic individuals at average risk is feasible and well-received.

背景:中国的结直肠癌(CRC)发病率正在稳步上升,其中晚期患者比例较高。这凸显了早期检测和预防措施对提高生存率的重要意义。粪便免疫化学检测(FIT)是全球推荐的一种CRC筛查方法,但在海南的应用研究却很有限。目的:评估FIT筛查在海南中危人群中的有效性和依从性,同时研究与FIT阳性结果相关的风险因素:这项基于人群的横断面研究对海南省5个城市和21个社区卫生服务中心的2000名40-75岁无症状者进行了FIT筛查。该研究于 2022 年 8 月至 2023 年 4 月进行,采用分层抽样法选择参与者。FIT结果呈阳性者随后接受了结肠镜检查。研究计算了确诊 CRC 和晚期腺瘤的阳性预测值,并使用 χ 2 检验和多变量逻辑回归分析了相关变量与 FIT 阳性结果之间的关系:共有 1788 名参与者完成了 FIT 筛查,中位年龄为 57 岁(四分位距:40-75)。其中男性 503 人(28.1%),女性 1285 人(71.9%),FIT 筛查合格率为 89.4%。FIT 的总体阳性率为 4.4% [1788 人中有 79 人;95% 置信区间 (CI):3%-5%]。海口市、三亚市、东方市、琼海市和五指山市的特异性阳性率分别为 9.6% (468 人中有 45 人;95%CI:8%-11%)、1.3%(445 人中有 6 人;95%CI:0.1%-3.1%)、2.7%(293 人中有 8 人;95%CI:1.2%-4.3%)、3.3%(276 人中有 9 人;95%CI:1.0%-6.3%)和 4.2%(406 人中有 11 人;95%CI:1.2%-7.3%)。研究发现,年龄、饮食习惯与 FIT 阳性结果之间存在显著关联。在 FIT 结果呈阳性的 79 名参与者中,55 人接受了结肠镜检查,符合率为 82.2%。其中,10 人的胃肠道干净,43 人有息肉或腺瘤,2 人确诊为 CRC,阳性预测值为 3.6%(95%CI:0.9%-4.2%)。在43名息肉或腺瘤患者中,8人被确诊为晚期腺瘤,晚期腺瘤率为14.5%(95%CI:10.1%-17.7%):结论:在海南地区,对无症状的一般风险人群进行 FIT 筛查 CRC 是可行的,而且很受欢迎。
{"title":"Application of fecal immunochemical test in colorectal cancer screening: A community-based, cross-sectional study in average-risk individuals in Hainan.","authors":"Fan Zeng, Da-Ya Zhang, Shi-Ju Chen, Run-Xiang Chen, Chen Chen, Shi-Mei Huang, Da Li, Xiao-Dong Zhang, Jia-Jia Chen, Cui-Yi Mo, Lei Gao, Jun-Tao Zeng, Jian-Xin Xiong, Zhai Chen, Fei-Hu Bai","doi":"10.4251/wjgo.v16.i8.3445","DOIUrl":"10.4251/wjgo.v16.i8.3445","url":null,"abstract":"<p><strong>Background: </strong>The incidence of colorectal cancer (CRC) in China is steadily rising, with a high proportion of advanced-stage diagnoses. This highlights the significance of early detection and prevention measures to enhance survival rates. Fecal immunochemical testing (FIT) is a globally recommended CRC screening method; however, limited research has been conducted on its application in Hainan.</p><p><strong>Aim: </strong>To assess the efficacy and adherence of FIT screening among average-risk individuals in Hainan, while also examining the risk factors associated with positive FIT results.</p><p><strong>Methods: </strong>This population-based cross-sectional study implemented FIT screening for CRC in 2000 asymptomatic participants aged 40-75 years from five cities and 21 community health centers in Hainan Province. The study was conducted from August 2022 to April 2023, employing a stratified sampling method to select participants. Individuals with positive FIT results subsequently underwent colonoscopy. Positive predictive values for confirmed CRC and advanced adenoma were calculated, and the relationship between relevant variables and positive FIT results was analyzed using <i>χ</i> <sup>2</sup> tests and multivariate logistic regression.</p><p><strong>Results: </strong>A total of 1788 participants completed the FIT screening, with a median age of 57 years (interquartile range: 40-75). Among them, 503 (28.1%) were males, and 1285 (71.9%) were females, resulting in an 89.4% compliance rate for FIT screening. The overall positivity rate of FIT was 4.4% [79 out of 1788; 95% confidence interval (CI): 3%-5%]. The specific positivity rates for Haikou, Sanya, Orient City, Qionghai City, and Wuzhishan City were 9.6% (45 of 468; 95%CI: 8%-11%), 1.3% (6 of 445; 95%CI: 0.1%-3.1%), 2.7% (8 of 293; 95%CI: 1.2%-4.3%), 3.3% (9 of 276; 95%CI: 1.0%-6.3%), and 4.2% (11 of 406; 95%CI: 1.2%-7.3%), respectively. Significant associations were found between age, dietary habits, and positive FIT results. Out of the 79 participants with positive FIT results, 55 underwent colonoscopy, demonstrating an 82.2% compliance rate. Among them, 10 had a clean gastrointestinal tract, 43 had polyps or adenomas, and 2 were confirmed to have CRC, yielding a positive predictive value of 3.6% (95%CI: 0.9%-4.2%). Among the 43 participants with polyps or adenomas, 8 were diagnosed with advanced adenomas, resulting in an advanced adenoma rate of 14.5% (95%CI: 10.1%-17.7%).</p><p><strong>Conclusion: </strong>In the Hainan region, FIT screening for CRC among asymptomatic individuals at average risk is feasible and well-received.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for the prognosis of colon cancer. 结肠癌预后的风险因素。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3738
Chu-Ying Wu, Kai Ye

A study on clinical outcomes and prognostic factors in T4N0M0 colon cancer patients after R0 resection revealed that ileostomy, T stage, right hemicolectomy, irregular follow-up, and CA199 level were independent risk factors affecting overall survival. T4-stage cancer invades the entire thickness of the intestinal tract, increasing the difficulty of treatment and the risk of recurrence, and requires a combination of chemotherapy, immunotherapy, and targeted therapy to control the spread of cancer cells. The prognosis of right hemicolectomy is significantly worse than that of left hemicolectomy, and right hemicolectomy is an independent risk factor for a poor prognosis. Advanced age, histopathological type, and lymph node metastasis are also risk factors for colon cancer.

一项关于R0切除术后T4N0M0结肠癌患者临床结局和预后因素的研究显示,回肠造口、T期、右半结肠切除术、不规则随访和CA199水平是影响总生存期的独立危险因素。T4期癌症侵犯肠道全层,增加了治疗难度和复发风险,需要结合化疗、免疫治疗和靶向治疗来控制癌细胞扩散。右半结肠切除术的预后明显差于左半结肠切除术,右半结肠切除术是预后不良的独立危险因素。高龄、组织病理学类型和淋巴结转移也是结肠癌的危险因素。
{"title":"Risk factors for the prognosis of colon cancer.","authors":"Chu-Ying Wu, Kai Ye","doi":"10.4251/wjgo.v16.i8.3738","DOIUrl":"10.4251/wjgo.v16.i8.3738","url":null,"abstract":"<p><p>A study on clinical outcomes and prognostic factors in T4N0M0 colon cancer patients after R0 resection revealed that ileostomy, T stage, right hemicolectomy, irregular follow-up, and CA199 level were independent risk factors affecting overall survival. T4-stage cancer invades the entire thickness of the intestinal tract, increasing the difficulty of treatment and the risk of recurrence, and requires a combination of chemotherapy, immunotherapy, and targeted therapy to control the spread of cancer cells. The prognosis of right hemicolectomy is significantly worse than that of left hemicolectomy, and right hemicolectomy is an independent risk factor for a poor prognosis. Advanced age, histopathological type, and lymph node metastasis are also risk factors for colon cancer.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334023/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Navigating the labyrinth of long non-coding RNAs in colorectal cancer: From chemoresistance to autophagy. 探索结直肠癌中长非编码 RNA 的迷宫:从化疗抗性到自噬。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3376
Jia-Mei Yu, Chong-Qi Sun, Huan-Huan Xu, Ya-Li Jiang, Xing-Yu Jiang, Si-Qi Ni, Ting-Yu Zhao, Ling-Xiang Liu

Long non-coding RNAs (lncRNAs), with transcript lengths exceeding 200 nucleotides and little or no protein-coding capacity, have been found to impact colorectal cancer (CRC) through various biological processes. LncRNA expression can regulate autophagy, which plays dual roles in the initiation and progression of cancers, including CRC. Abnormal expression of lncRNAs is associated with the emergence of chemoresistance. Moreover, it has been confirmed that targeting autophagy through lncRNA regulation could be a viable approach for combating chemoresistance. Two recent studies titled "Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506" and "Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription" revealed novel insights into lncRNAs associated with autophagy and oxaliplatin resistance in CRC, respectively. In this editorial, we particularly focus on the regulatory role of lncRNAs in CRC-related autophagy and chemoresistance since the regulation of chemotherapeutic sensitivity by intervening with the lncRNAs involved in the autophagy process has become a promising new approach for cancer treatment.

长非编码 RNA(lncRNA)的转录本长度超过 200 个核苷酸,几乎不具有编码蛋白质的能力,已被发现可通过各种生物学过程影响结直肠癌(CRC)。LncRNA 的表达可调控自噬,而自噬在癌症(包括 CRC)的发生和发展过程中扮演着双重角色。lncRNA 的异常表达与化疗耐药性的出现有关。此外,通过lncRNA调控自噬可能是对抗化疗耐药性的一种可行方法。最近两项题为 "Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506 "和 "Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription "的研究分别揭示了与CRC自噬和奥沙利铂耐药性相关的lncRNA的新见解。在这篇社论中,我们特别关注lncRNAs在CRC相关自噬和化疗耐药中的调控作用,因为通过干预参与自噬过程的lncRNAs来调节化疗敏感性已成为一种很有前景的癌症治疗新方法。
{"title":"Navigating the labyrinth of long non-coding RNAs in colorectal cancer: From chemoresistance to autophagy.","authors":"Jia-Mei Yu, Chong-Qi Sun, Huan-Huan Xu, Ya-Li Jiang, Xing-Yu Jiang, Si-Qi Ni, Ting-Yu Zhao, Ling-Xiang Liu","doi":"10.4251/wjgo.v16.i8.3376","DOIUrl":"10.4251/wjgo.v16.i8.3376","url":null,"abstract":"<p><p>Long non-coding RNAs (lncRNAs), with transcript lengths exceeding 200 nucleotides and little or no protein-coding capacity, have been found to impact colorectal cancer (CRC) through various biological processes. LncRNA expression can regulate autophagy, which plays dual roles in the initiation and progression of cancers, including CRC. Abnormal expression of lncRNAs is associated with the emergence of chemoresistance. Moreover, it has been confirmed that targeting autophagy through lncRNA regulation could be a viable approach for combating chemoresistance. Two recent studies titled \"Human β-defensin-1 affects the mammalian target of rapamycin pathway and autophagy in colon cancer cells through long non-coding RNA TCONS_00014506\" and \"Upregulated lncRNA PRNT promotes progression and oxaliplatin resistance of colorectal cancer cells by regulating HIPK2 transcription\" revealed novel insights into lncRNAs associated with autophagy and oxaliplatin resistance in CRC, respectively. In this editorial, we particularly focus on the regulatory role of lncRNAs in CRC-related autophagy and chemoresistance since the regulation of chemotherapeutic sensitivity by intervening with the lncRNAs involved in the autophagy process has become a promising new approach for cancer treatment.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma. 卡瑞珠单抗、阿帕替尼和肝动脉灌注化疗联合微波消融治疗晚期肝细胞癌。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3481
Meng-Xuan Zuo, Chao An, Yu-Zhe Cao, Jia-Yu Pan, Lu-Ping Xie, Xin-Jing Yang, Wang Li, Pei-Hong Wu

Background: Hepatic arterial infusion chemotherapy and camrelizumab plus apatinib (TRIPLET protocol) is promising for advanced hepatocellular carcinoma (Ad-HCC). However, the usefulness of microwave ablation (MWA) after TRIPLET is still controversial.

Aim: To compare the efficacy and safety of TRIPLET alone (T-A) vs TRIPLET-MWA (T-M) for Ad-HCC.

Methods: From January 2018 to March 2022, 217 Ad-HCC patients were retrospectively enrolled. Among them, 122 were included in the T-A group, and 95 were included in the T-M group. A propensity score matching (PSM) was applied to balance bias. Overall survival (OS) was compared using the Kaplan-Meier curve with the log-rank test. The overall objective response rate (ORR) and major complications were also assessed.

Results: After PSM, 82 patients were included both the T-A group and the T-M group. The ORR (85.4%) in the T-M group was significantly higher than that (65.9%) in the T-A group (P < 0.001). The cumulative 1-, 2-, and 3-year OS rates were 98.7%, 93.4%, and 82.0% in the T-M group and 85.1%, 63.1%, and 55.0% in the T-A group (hazard ratio = 0.22; 95% confidence interval: 0.10-0.49; P < 0.001). The incidence of major complications was 4.9% (6/122) in the T-A group and 5.3% (5/95) in the T-M group, which were not significantly different (P = 1.000).

Conclusion: T-M can provide better survival outcomes and comparable safety for Ad-HCC than T-A.

背景:肝动脉灌注化疗和坎瑞珠单抗加阿帕替尼(TRIPLET方案)对晚期肝细胞癌(Ad-HCC)有很好的疗效。然而,TRIPLET后的微波消融(MWA)是否有用仍存在争议。目的:比较单独TRIPLET(T-A)与TRIPLET-MWA(T-M)治疗Ad-HCC的疗效和安全性:方法:2018年1月至2022年3月,回顾性纳入217例Ad-HCC患者。其中,122人被纳入T-A组,95人被纳入T-M组。采用倾向评分匹配法(PSM)平衡偏倚。采用 Kaplan-Meier 曲线和对数秩检验比较总生存期(OS)。此外,还对总体客观反应率(ORR)和主要并发症进行了评估:PSM 后,T-A 组和 T-M 组共纳入 82 例患者。T-M组的ORR(85.4%)明显高于T-A组(65.9%)(P < 0.001)。T-M组的1年、2年和3年累积OS率分别为98.7%、93.4%和82.0%,T-A组分别为85.1%、63.1%和55.0%(危险比=0.22;95%置信区间:0.10-0.49;P<0.001)。T-A组主要并发症的发生率为4.9%(6/122),T-M组为5.3%(5/95),两者无显著差异(P = 1.000):结论:与T-A相比,T-M能为Ad-HCC提供更好的生存结果和相当的安全性。
{"title":"Camrelizumab, apatinib and hepatic artery infusion chemotherapy combined with microwave ablation for advanced hepatocellular carcinoma.","authors":"Meng-Xuan Zuo, Chao An, Yu-Zhe Cao, Jia-Yu Pan, Lu-Ping Xie, Xin-Jing Yang, Wang Li, Pei-Hong Wu","doi":"10.4251/wjgo.v16.i8.3481","DOIUrl":"10.4251/wjgo.v16.i8.3481","url":null,"abstract":"<p><strong>Background: </strong>Hepatic arterial infusion chemotherapy and camrelizumab plus apatinib (TRIPLET protocol) is promising for advanced hepatocellular carcinoma (Ad-HCC). However, the usefulness of microwave ablation (MWA) after TRIPLET is still controversial.</p><p><strong>Aim: </strong>To compare the efficacy and safety of TRIPLET alone (T-A) <i>vs</i> TRIPLET-MWA (T-M) for Ad-HCC.</p><p><strong>Methods: </strong>From January 2018 to March 2022, 217 Ad-HCC patients were retrospectively enrolled. Among them, 122 were included in the T-A group, and 95 were included in the T-M group. A propensity score matching (PSM) was applied to balance bias. Overall survival (OS) was compared using the Kaplan-Meier curve with the log-rank test. The overall objective response rate (ORR) and major complications were also assessed.</p><p><strong>Results: </strong>After PSM, 82 patients were included both the T-A group and the T-M group. The ORR (85.4%) in the T-M group was significantly higher than that (65.9%) in the T-A group (<i>P</i> < 0.001). The cumulative 1-, 2-, and 3-year OS rates were 98.7%, 93.4%, and 82.0% in the T-M group and 85.1%, 63.1%, and 55.0% in the T-A group (hazard ratio = 0.22; 95% confidence interval: 0.10-0.49; <i>P</i> < 0.001). The incidence of major complications was 4.9% (6/122) in the T-A group and 5.3% (5/95) in the T-M group, which were not significantly different (<i>P</i> = 1.000).</p><p><strong>Conclusion: </strong>T-M can provide better survival outcomes and comparable safety for Ad-HCC than T-A.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Colon cancer screening: What to choose? 结肠癌筛查:如何选择?
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3393
Martin Alonso Gomez Zuleta

Colorectal cancer is one of the predominant tumors in the world, primarily generated by a progression from polyp to cancer which can last several years, giving a great opportunity to the scientific community for its prevention by screening programs that can be done with invasive and non-invasive tests. In this issue, Lopes et al show us an excellent review of screening, its options, its advantages and disadvantages.

大肠癌是世界上最主要的肿瘤之一,主要是由息肉发展成癌症,可持续数年,这给科学界提供了通过筛查计划预防大肠癌的绝佳机会。在本期杂志中,洛佩斯等人向我们展示了有关筛查、筛查方案、筛查优缺点的精彩回顾。
{"title":"Colon cancer screening: What to choose?","authors":"Martin Alonso Gomez Zuleta","doi":"10.4251/wjgo.v16.i8.3393","DOIUrl":"10.4251/wjgo.v16.i8.3393","url":null,"abstract":"<p><p>Colorectal cancer is one of the predominant tumors in the world, primarily generated by a progression from polyp to cancer which can last several years, giving a great opportunity to the scientific community for its prevention by screening programs that can be done with invasive and non-invasive tests. In this issue, Lopes <i>et al</i> show us an excellent review of screening, its options, its advantages and disadvantages.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334042/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of acacetin on inhibition of apoptosis in Helicobacter pylori-infected gastric epithelial cell line. 阿卡西汀对抑制幽门螺旋杆菌感染的胃上皮细胞系凋亡的影响
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3624
Qi-Xi Yao, Zi-Yu Li, Hou-Le Kang, Xin He, Min Kang

Background: Helicobacter pylori (H. pylori) infection can cause extensive apoptosis of gastric epithelial cells, serving as a critical catalyst in the progression from chronic gastritis, gastrointestinal metaplasia, and atypical gastric hyperplasia to gastric carcinoma. Prompt eradication of H. pylori is paramount for ameliorating the pathophysiological conditions associated with chronic inflammation of the gastric mucosa and the primary prevention of gastric cancer. Acacetin, which has multifaceted pharmacological activities such as anti-cancer, anti-inflammatory, and antioxidative properties, has been extensively investigated across various domains. Nevertheless, the impact and underlying mechanisms of action of acacetin on H. pylori-infected gastric mucosal epithelial cells remain unclear.

Aim: To explore the defensive effects of acacetin on apoptosis in H. pylori-infected GES-1 cells and to investigate the underlying mechanisms.

Methods: GES-1 cells were treated with H. pylori and acacetin in vitro. Cell viability was assessed using the CCK-8 assay, cell mortality rate via lactate dehydrogenase assay, alterations in cell migration and healing capacities through the wound healing assay, rates of apoptosis via flow cytometry and TUNEL staining, and expression levels of apoptosis-associated proteins through western blot analysis.

Results: H. pylori infection led to decreased GES-1 cell viability, increased cell mortality, suppressed cell migration, increased rate of apoptosis, increased expressions of Bax and cle-caspase3, and decreased Bcl-2 expression. Conversely, acacetin treatment enhanced cell viability, mitigated apoptosis induced by H. pylori infection, and modulated the expression of apoptosis-regulatory proteins by upregulating Bcl-2 and downregulating Bax and cleaved caspase-3.

Conclusion: Acacetin significantly improved GES-1 cell viability and inhibited apoptosis in H. pylori-infected GES-1 cells, thereby exerting a protective effect on gastric mucosal epithelial cells.

背景:幽门螺杆菌(H. pylori)感染可导致胃上皮细胞大量凋亡,是慢性胃炎、胃肠道化生和不典型胃增生发展为胃癌的关键催化剂。及时根除幽门螺杆菌对于改善与胃黏膜慢性炎症相关的病理生理状况和胃癌的一级预防至关重要。乙酰丙酸具有抗癌、抗炎和抗氧化等多方面的药理作用,已在多个领域得到广泛研究。目的:探讨阿卡西汀对幽门螺杆菌感染的 GES-1 细胞凋亡的防御作用,并研究其潜在机制:方法:在体外用幽门螺杆菌和阿卡西汀处理 GES-1 细胞。方法:用幽门螺杆菌和阿卡西汀体外处理 GES-1 细胞,用 CCK-8 检测法评估细胞活力,用乳酸脱氢酶检测法评估细胞死亡率,用伤口愈合检测法评估细胞迁移和愈合能力的变化,用流式细胞仪和 TUNEL 染色法评估细胞凋亡率,用 Western 印迹分析法评估细胞凋亡相关蛋白的表达水平:结果:幽门螺杆菌感染导致 GES-1 细胞存活率降低、细胞死亡率增加、细胞迁移受抑制、细胞凋亡率增加、Bax 和 cle-caspase3 表达增加以及 Bcl-2 表达减少。相反,阿卡西汀处理可提高细胞活力,减轻幽门螺杆菌感染诱导的细胞凋亡,并通过上调 Bcl-2、下调 Bax 和裂解的 caspase-3 来调节细胞凋亡调节蛋白的表达:结论:阿卡西汀能明显提高幽门螺杆菌感染的 GES-1 细胞的活力,抑制细胞凋亡,从而对胃黏膜上皮细胞起到保护作用。
{"title":"Effect of acacetin on inhibition of apoptosis in <i>Helicobacter pylori</i>-infected gastric epithelial cell line.","authors":"Qi-Xi Yao, Zi-Yu Li, Hou-Le Kang, Xin He, Min Kang","doi":"10.4251/wjgo.v16.i8.3624","DOIUrl":"10.4251/wjgo.v16.i8.3624","url":null,"abstract":"<p><strong>Background: </strong><i>Helicobacter pylori</i> (<i>H. pylori</i>) infection can cause extensive apoptosis of gastric epithelial cells, serving as a critical catalyst in the progression from chronic gastritis, gastrointestinal metaplasia, and atypical gastric hyperplasia to gastric carcinoma. Prompt eradication of <i>H. pylori</i> is paramount for ameliorating the pathophysiological conditions associated with chronic inflammation of the gastric mucosa and the primary prevention of gastric cancer. Acacetin, which has multifaceted pharmacological activities such as anti-cancer, anti-inflammatory, and antioxidative properties, has been extensively investigated across various domains. Nevertheless, the impact and underlying mechanisms of action of acacetin on <i>H. pylori</i>-infected gastric mucosal epithelial cells remain unclear.</p><p><strong>Aim: </strong>To explore the defensive effects of acacetin on apoptosis in <i>H. pylori</i>-infected GES-1 cells and to investigate the underlying mechanisms.</p><p><strong>Methods: </strong>GES-1 cells were treated with <i>H. pylori</i> and acacetin in vitro. Cell viability was assessed using the CCK-8 assay, cell mortality rate <i>via</i> lactate dehydrogenase assay, alterations in cell migration and healing capacities through the wound healing assay, rates of apoptosis <i>via</i> flow cytometry and TUNEL staining, and expression levels of apoptosis-associated proteins through western blot analysis.</p><p><strong>Results: </strong><i>H. pylori</i> infection led to decreased GES-1 cell viability, increased cell mortality, suppressed cell migration, increased rate of apoptosis, increased expressions of Bax and cle-caspase3, and decreased Bcl-2 expression. Conversely, acacetin treatment enhanced cell viability, mitigated apoptosis induced by <i>H. pylori</i> infection, and modulated the expression of apoptosis-regulatory proteins by upregulating Bcl-2 and downregulating Bax and cleaved caspase-3.</p><p><strong>Conclusion: </strong>Acacetin significantly improved GES-1 cell viability and inhibited apoptosis in <i>H. pylori</i>-infected GES-1 cells, thereby exerting a protective effect on gastric mucosal epithelial cells.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334024/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic detection and diagnostic strategies for minute gastric cancer: A real-world observational study. 微小胃癌的内镜检测和诊断策略:真实世界观察研究。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3529
Xiao-Wei Ji, Jie Lin, Yan-Ting Wang, Jing-Jing Ruan, Jing-Hong Xu, Kai Song, Jian-Shan Mao

Background: Minute gastric cancers (MGCs) have a favorable prognosis, but they are too small to be detected by endoscopy, with a maximum diameter ≤ 5 mm.

Aim: To explore endoscopic detection and diagnostic strategies for MGCs.

Methods: This was a real-world observational study. The endoscopic and clinicopathological parameters of 191 MGCs between January 2015 and December 2022 were retrospectively analyzed. Endoscopic discoverable opportunity and typical neoplastic features were emphatically reviewed.

Results: All MGCs in our study were of a single pathological type, 97.38% (186/191) of which were differentiated-type tumors. White light endoscopy (WLE) detected 84.29% (161/191) of MGCs, and the most common morphology of MGCs found by WLE was protruding. Narrow-band imaging (NBI) secondary observation detected 14.14% (27/191) of MGCs, and the most common morphology of MGCs found by NBI was flat. Another three MGCs were detected by indigo carmine third observation. If a well-demarcated border lesion exhibited a typical neoplastic color, such as yellowish-red or whitish under WLE and brownish under NBI, MGCs should be diagnosed. The proportion with high diagnostic confidence by magnifying endoscopy with NBI (ME-NBI) was significantly higher than the proportion with low diagnostic confidence and the only visible groups (94.19% > 56.92% > 32.50%, P < 0.001).

Conclusion: WLE combined with NBI and indigo carmine are helpful for detection of MGCs. A clear demarcation line combined with a typical neoplastic color using nonmagnifying observation is sufficient for diagnosis of MGCs. ME-NBI improves the endoscopic diagnostic confidence of MGCs.

背景:微小胃癌(MGCs)的预后良好,但它们太小,无法通过内镜检测,最大直径≤5 mm:微型胃癌(MGCs)的预后良好,但其体积太小,无法通过内镜检测,最大直径≤5 mm:这是一项真实世界观察研究。回顾性分析了2015年1月至2022年12月期间191例MGCs的内镜和临床病理参数。结果:我们研究中的所有MGC均为单一病理类型,其中97.38%(186/191)为分化型肿瘤。白光内镜检查(WLE)发现了84.29%(161/191)的MGCs,WLE发现的MGCs最常见的形态是突出。窄带成像(NBI)二次观察发现了 14.14%(27/191)的 MGCs,NBI 发现的 MGCs 最常见的形态是扁平的。通过靛蓝胭脂红第三次观察还发现了 3 个 MGC。如果分界清楚的边界病变呈现典型的肿瘤颜色,如在 WLE 下呈黄红色或白色,而在 NBI 下呈褐色,则应诊断为 MGC。通过放大内镜和 NBI(ME-NBI)诊断信心高的比例明显高于诊断信心低的比例和唯一可见组(94.19% > 56.92% > 32.50%,P < 0.001):结论:WLE 结合 NBI 和靛胭脂红有助于检测 MGCs。使用非放大镜观察,一条清晰的分界线结合典型的肿瘤颜色足以诊断 MGCs。ME-NBI 提高了内镜诊断 MGCs 的可信度。
{"title":"Endoscopic detection and diagnostic strategies for minute gastric cancer: A real-world observational study.","authors":"Xiao-Wei Ji, Jie Lin, Yan-Ting Wang, Jing-Jing Ruan, Jing-Hong Xu, Kai Song, Jian-Shan Mao","doi":"10.4251/wjgo.v16.i8.3529","DOIUrl":"10.4251/wjgo.v16.i8.3529","url":null,"abstract":"<p><strong>Background: </strong>Minute gastric cancers (MGCs) have a favorable prognosis, but they are too small to be detected by endoscopy, with a maximum diameter ≤ 5 mm.</p><p><strong>Aim: </strong>To explore endoscopic detection and diagnostic strategies for MGCs.</p><p><strong>Methods: </strong>This was a real-world observational study. The endoscopic and clinicopathological parameters of 191 MGCs between January 2015 and December 2022 were retrospectively analyzed. Endoscopic discoverable opportunity and typical neoplastic features were emphatically reviewed.</p><p><strong>Results: </strong>All MGCs in our study were of a single pathological type, 97.38% (186/191) of which were differentiated-type tumors. White light endoscopy (WLE) detected 84.29% (161/191) of MGCs, and the most common morphology of MGCs found by WLE was protruding. Narrow-band imaging (NBI) secondary observation detected 14.14% (27/191) of MGCs, and the most common morphology of MGCs found by NBI was flat. Another three MGCs were detected by indigo carmine third observation. If a well-demarcated border lesion exhibited a typical neoplastic color, such as yellowish-red or whitish under WLE and brownish under NBI, MGCs should be diagnosed. The proportion with high diagnostic confidence by magnifying endoscopy with NBI (ME-NBI) was significantly higher than the proportion with low diagnostic confidence and the only visible groups (94.19% > 56.92% > 32.50%, <i>P</i> < 0.001).</p><p><strong>Conclusion: </strong>WLE combined with NBI and indigo carmine are helpful for detection of MGCs. A clear demarcation line combined with a typical neoplastic color using nonmagnifying observation is sufficient for diagnosis of MGCs. ME-NBI improves the endoscopic diagnostic confidence of MGCs.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune-related gene characteristics: A new chapter in precision treatment of gastric cancer. 免疫相关基因特征:胃癌精准治疗的新篇章。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3372
Lei Gao, Qiang Lin

Gastric cancer ranks as the sixth most prevalent cancer worldwide. In recent research within the realm of gastric cancer treatment, the identification and application of immune-related genetic features have emerged as groundbreaking advancements. The study by Ma et al, which developed a prognostic model based on 10 genes, categorizes patients into high and low-risk groups to predict their responsiveness to immune checkpoint inhibitor therapy. This research underscores the potential of immune-related genes as biomarkers for personalized treatment, offering insights into tumor mutation burden and immune phenotype scores. We advocate for further validation, understanding of biological mechanisms, and integration of diverse datasets to enhance the model's predictive accuracy and clinical application, marking a significant step towards personalized and precise treatment for gastric cancer.

胃癌是全球发病率第六高的癌症。在胃癌治疗领域的最新研究中,免疫相关基因特征的识别和应用取得了突破性进展。Ma 等人的研究基于 10 个基因建立了一个预后模型,将患者分为高危和低危两组,以预测他们对免疫检查点抑制剂治疗的反应性。这项研究强调了免疫相关基因作为个性化治疗生物标志物的潜力,为肿瘤突变负荷和免疫表型评分提供了见解。我们主张进一步验证、了解生物机制并整合不同的数据集,以提高模型的预测准确性和临床应用,从而向胃癌的个性化精准治疗迈出重要一步。
{"title":"Immune-related gene characteristics: A new chapter in precision treatment of gastric cancer.","authors":"Lei Gao, Qiang Lin","doi":"10.4251/wjgo.v16.i8.3372","DOIUrl":"10.4251/wjgo.v16.i8.3372","url":null,"abstract":"<p><p>Gastric cancer ranks as the sixth most prevalent cancer worldwide. In recent research within the realm of gastric cancer treatment, the identification and application of immune-related genetic features have emerged as groundbreaking advancements. The study by Ma <i>et al</i>, which developed a prognostic model based on 10 genes, categorizes patients into high and low-risk groups to predict their responsiveness to immune checkpoint inhibitor therapy. This research underscores the potential of immune-related genes as biomarkers for personalized treatment, offering insights into tumor mutation burden and immune phenotype scores. We advocate for further validation, understanding of biological mechanisms, and integration of diverse datasets to enhance the model's predictive accuracy and clinical application, marking a significant step towards personalized and precise treatment for gastric cancer.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current and future research directions in cellular metabolism of colorectal cancer: A bibliometric analysis. 大肠癌细胞代谢的当前和未来研究方向:文献计量分析。
IF 2.5 4区 医学 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-08-15 DOI: 10.4251/wjgo.v16.i8.3732
Bo-Wen Jiang, Xiu-Hua Zhang, Rui Ma, Wen-Yu Luan, Yan-Dong Miao

The primary aim of this study was to analyze the evolving trends and key focal points in research on cellular metabolism of colorectal cancer (CRC). Relevant publications on cellular metabolism in CRC were sourced from the Science Citation Index Expanded within the Web of Science Core Collection database. Bibliometric analysis and visualization were conducted using VOSviewer (version 1.6.18) software and CiteSpace 6.1.R6 (64-bit) Basic. A comprehensive compilation of 4722 English-language publications, covering the period from January 1, 1991 to December 31, 2022, was carefully identified and included in the analysis. Among the authors, "Ogino, Shuji" contributed the most publications in this field, while "Giovannucci, E" garnered the highest number of citations. The journal "Cancer Research" ranked first in both publication volume and citations. Institutionally, "Shanghai Jiao Tong University" emerged as the top contributor in terms of published articles, while "Harvard University" led in citation impact. In country-based analysis, the United States held the top position in both publication output and citations, closely followed by China. The increasing recognition of the significance of cellular metabolism in CRC underscores its potential for novel therapeutic approaches aimed at improving CRC management and prognosis.

本研究的主要目的是分析结直肠癌(CRC)细胞代谢研究的发展趋势和关键焦点。有关 CRC 细胞代谢的相关论文均来自科学网核心收藏数据库中的科学引文索引扩展版。使用 VOSviewer(1.6.18 版)软件和 CiteSpace 6.1.R6(64 位)Basic 进行了文献计量分析和可视化。对 1991 年 1 月 1 日至 2022 年 12 月 31 日期间的 4722 篇英文出版物进行了全面汇编和仔细识别,并将其纳入分析。在这些作者中,"Ogino, Shuji "在该领域发表的论文最多,而 "Giovannucci, E "则获得了最多的引用次数。癌症研究》杂志的发表量和引用量均居首位。从机构来看,"上海交通大学 "在发表文章方面贡献最大,而 "哈佛大学 "在引用影响方面居首位。在基于国家的分析中,美国的论文发表量和被引用次数均居首位,中国紧随其后。人们日益认识到细胞代谢在 CRC 中的重要性,这凸显了细胞代谢对新型治疗方法的潜力,而新型治疗方法旨在改善 CRC 的管理和预后。
{"title":"Current and future research directions in cellular metabolism of colorectal cancer: A bibliometric analysis.","authors":"Bo-Wen Jiang, Xiu-Hua Zhang, Rui Ma, Wen-Yu Luan, Yan-Dong Miao","doi":"10.4251/wjgo.v16.i8.3732","DOIUrl":"10.4251/wjgo.v16.i8.3732","url":null,"abstract":"<p><p>The primary aim of this study was to analyze the evolving trends and key focal points in research on cellular metabolism of colorectal cancer (CRC). Relevant publications on cellular metabolism in CRC were sourced from the Science Citation Index Expanded within the Web of Science Core Collection database. Bibliometric analysis and visualization were conducted using VOSviewer (version 1.6.18) software and CiteSpace 6.1.R6 (64-bit) Basic. A comprehensive compilation of 4722 English-language publications, covering the period from January 1, 1991 to December 31, 2022, was carefully identified and included in the analysis. Among the authors, \"Ogino, Shuji\" contributed the most publications in this field, while \"Giovannucci, E\" garnered the highest number of citations. The journal \"<i>Cancer Research</i>\" ranked first in both publication volume and citations. Institutionally, \"Shanghai Jiao Tong University\" emerged as the top contributor in terms of published articles, while \"Harvard University\" led in citation impact. In country-based analysis, the United States held the top position in both publication output and citations, closely followed by China. The increasing recognition of the significance of cellular metabolism in CRC underscores its potential for novel therapeutic approaches aimed at improving CRC management and prognosis.</p>","PeriodicalId":23762,"journal":{"name":"World Journal of Gastrointestinal Oncology","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
World Journal of Gastrointestinal Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1